Chemistry:LM11A-31

From HandWiki

LM11A-31 is an experimental drug developed for Alzheimer's disease and Huntington's disease.[1][2][3][4][5][6][7][8]

References

  1. ↑ Simmons, Danielle A.; Knowles, Juliet K.; Belichenko, Nadia P.; Banerjee, Gargi; Finkle, Carly; Massa, Stephen M.; Longo, Frank M. (2014-08-25). "A Small Molecule p75NTR Ligand, LM11A-31, Reverses Cholinergic Neurite Dystrophy in Alzheimer's Disease Mouse Models with Mid- to Late-Stage Disease Progression". PLOS ONE 9 (8). doi:10.1371/journal.pone.0102136. ISSN 1932-6203. PMID 25153701. Bibcode: 2014PLoSO...9j2136S. 
  2. ↑ Elshaer, Sally L.; Alwhaibi, Abdulrahman; Mohamed, Riyaz; Lemtalsi, Tahira; Coucha, Maha; Longo, Frank M.; El-Remessy, Azza B. (2019). "Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway". Diabetologia 62 (8): 1488–1500. doi:10.1007/s00125-019-4885-2. ISSN 0012-186X. PMID 31073629. 
  3. ↑ Simmons, Danielle A.; Mills, Brian D.; Butler III, Robert R.; Kuan, Jason; McHugh, Tyne L.M.; Akers, Carolyn; Zhou, James; Syriani, Wassim et al. (2021). "Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31". Neurotherapeutics (Elsevier BV) 18 (2): 1039–1063. doi:10.1007/s13311-021-01023-8. ISSN 1878-7479. PMID 33786806. 
  4. ↑ Nasoohi, Sanaz; Tayefeh Ghahremani, Pargol; Alehossein, Parsa; Elyasizadeh, Siyamak; BaniArdalan, Soha; Ismael, Saifudeen; Vatanpour, Hossein; Ahmadiani, Abolhassan et al. (2023). "The p75 neurotrophin receptor inhibitor, LM11A-31, ameliorates acute stroke injury and modulates astrocytic proNGF". Experimental Neurology (Elsevier BV) 359. doi:10.1016/j.expneurol.2022.114161. ISSN 0014-4886. PMID 35787888. 
  5. ↑ Simmons, Danielle A; James, Michelle L; Belichenko, Nadia P; Semaan, Sarah; Condon, Christina; Kuan, Jason; Shuhendler, Adam J; Miao, Zheng et al. (2018-08-15). "TSPO–PET imaging using [18FPBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31"]. Human Molecular Genetics 27 (16): 2893–2912. doi:10.1093/hmg/ddy202. ISSN 0964-6906. PMID 29860333. 
  6. ↑ Nguyen, Thuy-Vi V.; Crumpacker, Rachel H.; Calderon, Kylie E.; Garcia, Frankie G.; Zbesko, Jacob C.; Frye, Jennifer B.; Gonzalez, Selena; Becktel, Danielle A. et al. (2021-12-10). "Post-Stroke Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Attenuates Chronic Changes in Brain Metabolism, Increases Neurotransmitter Levels, and Improves Recovery". Journal of Pharmacology and Experimental Therapeutics (American Society for Pharmacology & Experimental Therapeutics (ASPET)) 380 (2): 126–141. doi:10.1124/jpet.121.000711. ISSN 0022-3565. PMID 34893553. 
  7. ↑ Yin, Guo Nan; Ock, Jiyeon; Limanjaya, Anita; Minh, Nguyen Naht; Hong, Soon-Sun; Yang, Tao; Longo, Frank M.; Ryu, Ji-Kan et al. (2021). "Oral Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Improves Erectile Function in a Mouse Model of Cavernous Nerve Injury". The Journal of Sexual Medicine 18 (1): 17–28. doi:10.1016/j.jsxm.2020.10.015. PMID 33243690. 
  8. ↑ Shanks, Hayley R. C.; Börjesson-Hanson, Anne; Windisch, Manfred; Massa, Stephen M.; Longo, Frank M.; Schmitz, Taylor W. (December 2022). "Age-dependent effects of the p75 neurotrophin receptor modulator LM11A-31 on Alzheimer's disease biomarkers in a 26-week safety and exploratory endpoint trial". Alzheimer's & Dementia 18 (S10). doi:10.1002/alz.069079. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:LM11A-31&oldid=4035378"